Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.39 |
| ▸ | IP6K3 | Q96PC2 | 2/20 | 0.39 |
| ▸ | IP6K2 | Q9UHH9 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | LDHB | P07195 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25412023 | 0.86 | MAPT (0.60) | MAPTSMN1; SMN2LMNATP53KDM4E | |
| SCHEMBL17454468 | 0.82 | LMNA (0.47) | MAPTSMN1; SMN2LMNACYP1A2TP53 | |
| SCHEMBL4314264 | 0.81 | ESR1 (0.53) | MAPTSMN1; SMN2ALOX15LMNAKDM4E | |
| SCHEMBL21819051 | 0.79 | ALDH1A1 (0.51) | SMN1; SMN2TP53HIF1AKMT2AMCL1 | |
| SCHEMBL13576767 | 0.79 | KEAP1 (0.41) | SMN1; SMN2LMNACYP1A2TP53HIF1A | |
| SCHEMBL19900067 | 0.79 | SCD5 (0.52) | MAPTSMN1; SMN2LMNACYP1A2KDM4E | |
| SCHEMBL17442847 | 0.79 | MAPT (0.42) | MAPTSMN1; SMN2ALOX15LMNACYP1A2 | |
| SCHEMBL22672604 | 0.79 | TBK1 (0.44) | MAPTSMN1; SMN2LMNACYP1A2KDM4E | |
| SCHEMBL14564409 | 0.76 | MAPT (0.78) | MAPTSMN1; SMN2ALOX15LMNATP53 | |
| SCHEMBL492850 | 0.74 | LMNA (0.66) | MAPTSMN1; SMN2ALOX15LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361920-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2020-11-19 | — | — | US | disclosed |
| WO-2018059314-A1 | AZABICYCLE DERIVATIVES AND PREPARATION METHOD AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2018-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361920-A1 | ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF | SLC10A1, NR1H4, SLC10A2 | MAPT 3921/4885SMN1; SMN2 4610/4885ALOX15 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.